A narrative review about cognitive impairment in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD): Another matter to face through a holistic approach

Meroni, Marica; Longo, Miriam; Paolini, Erika; Dongiovanni, Paola

doi:10.1016/j.jare.2024.02.007

Cited by 2 publications

(4 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, changes in depressive symptoms were related to an improvement in HDL-c and adiponectin, which are related to MASLD. Several studies evidenced that the severity of liver diseases was related to psychiatric disorders [ 10 , 65 ]. This fact confirmed our results, showing that depressive symptoms affect and predict the presence of MASLD along with HDL-c, TG, BMI, and liver stiffness in the same combination panel after 24 months of dietary intervention.…”

Section: Discussionmentioning

confidence: 99%

“…Pro-inflammatory cytokines produced by visceral adipose tissue (VAT) in individuals with metabolic dysfunction contribute to the onset of insulin resistance (IR), hepatic lipotoxicity, and MASLD [ 9 ]. Chronic systemic inflammation, hyperammonemia, genetic predisposition, and intestinal dysbiosis may also collectively contribute to cognitive decline in MASLD patients, leading to depression, anxiety, reduced concentration and processing speed, reduced memory, and sleepiness [ 10 ]. Up to 70% of MASLD patients suffer from depression, memory problems, confusion, and poor concentration, greatly reducing their quality of life [ 11 ], their ability to perform daily activities, and their work productivity [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

“…Lifestyle factors, like dietary patterns, have shifted, leading to an increased prevalence of obesity and IR, while lifestyles have become increasingly sedentary [ 4 ]. Moreover, unhealthy dietary patterns and lifestyle behaviors exacerbate the inflammatory environment and accelerate cognitive decline [ 10 ]. It is important to focus on these interventions because they have shown promising outcomes in managing the condition [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Multipanel Approach including miRNAs, Inflammatory Markers, and Depressive Symptoms for Metabolic Dysfunction-Associated Steatotic Liver Disease Diagnosis during 2-Year Nutritional Intervention

Tobaruela-Resola,

Riezu-Boj,

Milagro

et al. 2024

Nutrients

View full text Add to dashboard Cite

Metabolic dysfunction-associated steatotic liver disease (MASLD), with a prevalence of 30% of adults globally, is considered a multifactorial disease. There is a lack of effective non-invasive methods for accurate diagnosis and monitoring. Therefore, this study aimed to explore associations between changes in circulating miRNA levels, inflammatory markers, and depressive symptoms with hepatic variables in MASLD subjects and their combined potential to predict the disease after following a dietary intervention. Biochemical markers, body composition, circulating miRNAs and hepatic and psychological status of 55 subjects with MASLD with obesity and overweight from the FLiO study were evaluated by undergoing a 6-, 12- and 24-month nutritional intervention. The highest accuracy values of combined panels to predict the disease were identified after 24 months. A combination panel that included changes in liver stiffness, high-density lipoprotein cholesterol (HDL-c), body mass index (BMI), depressive symptoms, and triglycerides (TG) yielded an AUC of 0.90. Another panel that included changes in hepatic fat content, total cholesterol (TC), miR15b-3p, TG, and depressive symptoms revealed an AUC of 0.89. These findings identify non-invasive biomarker panels including circulating miRNAs, inflammatory markers, depressive symptoms and other metabolic variables for predicting MASLD presence and emphasize the importance of precision nutrition in MASLD management and the sustained adherence to healthy lifestyle patterns.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Multipanel Approach including miRNAs, Inflammatory Markers, and Depressive Symptoms for Metabolic Dysfunction-Associated Steatotic Liver Disease Diagnosis during 2-Year Nutritional Intervention

Tobaruela-Resola,

Riezu-Boj,

Milagro

et al. 2024

Nutrients

View full text Add to dashboard Cite

show abstract

“…Анализ в подгруппах показал, что у пациентов с прогрессирующим течением MASLD (ОР 3,60, 95% ДИ 2,10-6,18; p<0,01) отмечается более высокий риск возникновения СД, чем у пациентов с MASLD меньшей степени тяжести (ОР 1,63, 95% ДИ 1,0-2,45; p=0,02) [9]. Ухудшение когнитивных функций при MASLD приводит к снижению концентрации внимания, скорости обработки информации и памяти, развитию сонливости, а также к тревоге и депрессии [12].…”

Section: The Clinician's View On the Advantages And Contradictions Of...unclassified

The clinician's view on the advantages and contradictions of the new nomenclature of steatotic liver disease: A review

Pavlov,

Teplyuk,

Lazebnik

et al. 2024

Terapevticheskii arkhiv

View full text Add to dashboard Cite

In September 2023, the European Association for the Study of the Liver (EASL) updated the disease nomenclature for non-alcoholic (metabolically associated) fatty liver disease. The goals of the revision were to increase awareness among health care professionals, civil society and patients about the disease, its course, treatment and outcomes; combating stigma; focusing on the initial etiological factor, including the main (cardiometabolic) risk of disease progression; improved diagnosis based on disease biomarkers; positive impact on the potency to search for new drugs; the ability to provide personalized medical care. The terms “non-alcoholic” and “fatty” were considered stigmatizing, and therefore, it was proposed to use the term steatotic liver disease (SLD) as the name of this nosology. The terms non-alcoholic fatty liver disease (NAFLD) or metabolic associated fatty liver disease (MAFLD) have been replaced by the term metabolic dysfunction-associated steatotic liver disease (MASLD). In the case of being combined with an alcohol factor, a diagnosis in which metabolic dysfunction is combined with alcoholic liver disease is referred to as MetALD. The fundamental principle in the diagnosis of MASLD is the presence of at least one of the cardiometabolic risk factors. Alcohol consumption interacts with cardiometabolic risk factors and increases the risk of SLD decompensation. The term nonalcoholic steatohepatitis (NASH), according to the new nomenclature, has been replaced by the term metabolic dysfunction-associated steatohepatitis (MASH). The adoption of the new nomenclature should help to increase awareness about the disease, its course and outcomes, as well as improve the quality of diagnosis and treatment.

show abstract

A narrative review about cognitive impairment in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD): Another matter to face through a holistic approach

Cited by 2 publications

References 103 publications

Multipanel Approach including miRNAs, Inflammatory Markers, and Depressive Symptoms for Metabolic Dysfunction-Associated Steatotic Liver Disease Diagnosis during 2-Year Nutritional Intervention

Multipanel Approach including miRNAs, Inflammatory Markers, and Depressive Symptoms for Metabolic Dysfunction-Associated Steatotic Liver Disease Diagnosis during 2-Year Nutritional Intervention

The clinician's view on the advantages and contradictions of the new nomenclature of steatotic liver disease: A review

Contact Info

Product

Resources

About